Canine Pipeline

KindredBio is pursuing a multi-pronged approach toward atopic dermatitis.

KindredBio reported positive topline results from its pilot field effectiveness study of tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin-31, for the treatment of atopic dermatitis in dogs. Pivotal efficacy study commenced in the fourth quarter of 2020.

We reported positive results from our pilot laboratory study of our interleukin-4R molecule, including evidence of positive efficacy and dose response. A second pilot study to further assess dosing commenced in the 3Q 2020.

The company reported positive results from its pilot efficacy study of its canine IL-4/13 SINK molecule in the first quarter of 2020. An initial pilot study for IL-17 has also been completed and the molecule was well-tolerated. Both programs are currently on hold pending further funding or partnering capital.